Simvastatin treatment promotes proliferation of human dental pulp stem cells via modulating PI3K/AKT/miR‐9/KLF5 signalling pathway

Simvastatin serves as an effective therapeutic potential in the treatment of dental disease via alternating proliferation of dental pulp stem cells. First, western‐blot and real‐time quantitative PCR were used to detect the effect of simvastatin or LY294002 on the expression levels of AKT, miR‐9 and KLF5, or determine the effect of miR‐9. Simvastatin, KLF5 and AKT significantly enhanced the proliferation of pulp stem cells, whilst this effect induced by simvastatin was suppressed by LY294002, AKT siRNA, KLF5 siRNA and miR‐9, and simvastatin dose‐dependently upregulated the expression of PI3K. Furthermore, simvastatin upregulated PI3K and p‐AKT expression in a concentration‐dependent manner. LY294002 abrogated the upregulation of p‐AKT expression levels induced by simvastatin, and LY294002 induced the miR‐9 expression and simvastatin dose‐dependently inhibited the expression of miR‐9, by contrast, LY294002 reduced the KLF5 expression and simvastatin dose‐dependently promoted the expression of KLF5. And using computational analysis, KLF5 was found to be a candidate target gene of miR‐9, and which was further verified using luciferase assay. Finally, the level of KLF5 in cells was much lower following the transfection with miR‐9 and KLF5 siRNA, and the level of AKT mRNA in cells was significantly inhibited after transfection with AKT siRNA than control. These findings suggested simvastatin could promote the proliferation of pulp stem cells, possibly by suppressing the expression of miR‐9 via activating the PI3K/AKT signalling pathway, and the downregulation of miR‐9 upregulated the expression of its target gene, KLF5, which is directly responsible for the enhanced proliferation of pulp stem cells.